Approval · Notice of Compliance 16160 · 2014
ACT DUTASTERIDE: Notice of Compliance 16160
Issued October 3, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16160
- Date
- October 3, 2014
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- New presentation
- Therapeutic class
- Type I and II 5 alpha-reductase inhibitor
- Canadian reference product
- AVODART (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT DUTASTERIDE | 02412691 | Cancelled Post Market |
Medicinal ingredients
- DUTASTERIDE 0.5 MG per CAP